Market Research Logo

Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2015

Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2015’, provides an overview of the Relapsing Multiple Sclerosis (RMS)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsing Multiple Sclerosis (RMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Multiple Sclerosis (RMS) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Relapsing Multiple Sclerosis (RMS)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Relapsing Multiple Sclerosis (RMS) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Relapsing Multiple Sclerosis (RMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Relapsing Multiple Sclerosis (RMS) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Relapsing Multiple Sclerosis (RMS)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Relapsing Multiple Sclerosis (RMS) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Relapsing Multiple Sclerosis (RMS) Overview
Therapeutics Development
Pipeline Products for Relapsing Multiple Sclerosis (RMS) - Overview
Relapsing Multiple Sclerosis (RMS) - Therapeutics under Development by Companies
Relapsing Multiple Sclerosis (RMS) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Relapsing Multiple Sclerosis (RMS) - Products under Development by Companies
Relapsing Multiple Sclerosis (RMS) - Companies Involved in Therapeutics Development
AbbVie Inc.
Actelion Ltd
BIOCAD
Cognosci, Inc.
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
Merck KGaA
Pfenex Inc.
Receptos, Inc.
VivaCell Biotechnology Espana S.L.
Relapsing Multiple Sclerosis (RMS) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles ABT-555 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cladribine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
COG-133 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DC-TAB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GZ-402668 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon beta-1a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon beta-1b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ocrelizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ozanimod hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
peginterferon beta 1a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-726 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ponesimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VCE-0032 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Relapsing Multiple Sclerosis (RMS) - Recent Pipeline Updates
Relapsing Multiple Sclerosis (RMS) - Dormant Projects
Relapsing Multiple Sclerosis (RMS) - Discontinued Products
Relapsing Multiple Sclerosis (RMS) - Product Development Milestones
Featured News & Press Releases
Oct 08, 2015: Roche’s ocrelizumab first investigational medicine to show positive pivotal study results in both relapsing and primary progressive forms of multiple sclerosis
Dec 22, 2014: Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
Jun 09, 2014: Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis
Jan 06, 2014: Receptos Begins Enrollment of Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
Jun 05, 2013: Receptos Provides Update On Progress Of Lead Product Candidate RPC1063
Jan 17, 2012: Genentech Recruits Investigators For Two Phase III Studies Comparing Ocrelizumab To Rebif In People With Relapsing Multiple Sclerosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Relapsing Multiple Sclerosis (RMS), H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Relapsing Multiple Sclerosis (RMS) - Pipeline by AbbVie Inc., H2 2015
Relapsing Multiple Sclerosis (RMS) - Pipeline by Actelion Ltd, H2 2015
Relapsing Multiple Sclerosis (RMS) - Pipeline by BIOCAD, H2 2015
Relapsing Multiple Sclerosis (RMS) - Pipeline by Cognosci, Inc., H2 2015
Relapsing Multiple Sclerosis (RMS) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Relapsing Multiple Sclerosis (RMS) - Pipeline by Genzyme Corporation, H2 2015
Relapsing Multiple Sclerosis (RMS) - Pipeline by Merck KGaA, H2 2015
Relapsing Multiple Sclerosis (RMS) - Pipeline by Pfenex Inc., H2 2015
Relapsing Multiple Sclerosis (RMS) - Pipeline by Receptos, Inc., H2 2015
Relapsing Multiple Sclerosis (RMS) - Pipeline by VivaCell Biotechnology Espana S.L., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Relapsing Multiple Sclerosis (RMS) Therapeutics - Recent Pipeline Updates, H2 2015
Relapsing Multiple Sclerosis (RMS) - Dormant Projects, H2 2015
Relapsing Multiple Sclerosis (RMS) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Relapsing Multiple Sclerosis (RMS), H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report